Abstract
A series of Val-Leu based peptidic aldehydes containing either a furan or thiophene at the Nterminus was prepared and assayed against ovine m-calpain. In general, potency is favoured by a 2- substituted (rather than 3-substituted) heterocycle, a thiophene rather than a furan, and a shorter chain length at the N-terminus. Molecular docking experiments provide some rationale for these observations.
Keywords: Calpain inhibitors, peptidic aldehydes, synthesis, heterocycles
Protein & Peptide Letters
Title: N-Heterocyclic Dipeptide Aldehyde Calpain Inhibitors
Volume: 16 Issue: 12
Author(s): Seth A. Jones, Matthew A. Jones, Stephen B. McNabb, Steven G. Aitken, James M. Coxon and Andrew D. Abell
Affiliation:
Keywords: Calpain inhibitors, peptidic aldehydes, synthesis, heterocycles
Abstract: A series of Val-Leu based peptidic aldehydes containing either a furan or thiophene at the Nterminus was prepared and assayed against ovine m-calpain. In general, potency is favoured by a 2- substituted (rather than 3-substituted) heterocycle, a thiophene rather than a furan, and a shorter chain length at the N-terminus. Molecular docking experiments provide some rationale for these observations.
Export Options
About this article
Cite this article as:
Jones A. Seth, Jones A. Matthew, McNabb B. Stephen, Aitken G. Steven, Coxon M. James and Abell D. Andrew, N-Heterocyclic Dipeptide Aldehyde Calpain Inhibitors, Protein & Peptide Letters 2009; 16 (12) . https://dx.doi.org/10.2174/092986609789839296
DOI https://dx.doi.org/10.2174/092986609789839296 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Critical Role of Vascular Endothelial Growth Factor in Tumor Angiogenesis
Current Cancer Drug Targets Innovative Research Financing for the 21<sup>st</sup> Century: A Case Narrative in How Technology Transfer and Entrepreneurship Supported the Development of a Prototype Cognitive Prosthetic
Technology Transfer and Entrepreneurship (Discontinued) Inhibitors of the Microsomal Prostaglandin E2 Synthase-1 as Alternative to Non Steroidal Anti-Inflammatory Drugs (NSAIDs) – A Critical Review
Current Medicinal Chemistry Insulin and the Brain
Current Diabetes Reviews Tetramethoxyluteolin for the Treatment of Neurodegenerative Diseases
Current Topics in Medicinal Chemistry An Update on Drug Interactions with the Herbal Medicine Ginkgo biloba
Current Drug Metabolism Anti-Inflammatory Effects of Antidepressants: Possibilities for Preventives Against Alzheimers Disease
Central Nervous System Agents in Medicinal Chemistry The Innate Immunity in Alzheimer Disease- Relevance to Pathogenesis and Therapy
Current Pharmaceutical Design Phase II and Pharmacological Study of Oral Docetaxel Plus Cyclosporin A in Anthracycline Pre-Treated Metastatic Breast Cancer
Current Clinical Pharmacology Neurotrophic Factors for Retinal Ganglion Cell Neuropathy - With a Special Reference to Diabetic Neuropathy in the Retina
Current Diabetes Reviews Dasatinib: An Anti-Tumour Agent via Src Inhibition
Current Drug Targets Adjudin - A Male Contraceptive with Other Biological Activities
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Castration Resistant Prostate Cancer: From Emerging Molecular Pathways to Targeted Therapeutic Approaches
Clinical Cancer Drugs An Arylidene-Thiazolidinedione Derivative, GPU-4, without PPARγ Activation, Reduces Retinal Neovascularization
Current Neurovascular Research Treatment of Chronic Pain with Drugs that Modulate Central Nervous System Serotonin and Norepinephrine
Current Drug Therapy Severe Preeclampsia
Current Women`s Health Reviews Recombinant Tissue-Type Plasminogen Activator (Alteplase) in the Management of Acute Ischemic Stroke: A Review of its Pharmacological Properties, Efficacy, Safety and Pharmacoeconomic Aspects
Current Drug Therapy Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines
Current Cancer Drug Targets Natural Substances in the Treatment of Cystic Fibrosis
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Modulation of the TRPV1 Channel: Current Clinical Trials and Recent Patents with Focus on Neurological Conditions
Recent Patents on CNS Drug Discovery (Discontinued)